Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

por Pavan, A., Attili, I., Pasello, G., Guarneri, V., Conte, P. F., Bonanno, L.
Publicado 2019

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials

por Guarneri, V., Griguolo, G., Miglietta, F., Conte, P.F., Dieci, M.V., Girardi, F.
Publicado 2022

Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)

por Baldini, E, Ardizzoni, A, Prochilo, T, Cafferata, M A, Boni, L, Tibaldi, C, Neumaier, C, Conte, P F, Rosso, R
Publicado 2001

Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based c...

por Buda, A, Floriani, I, Rossi, R, Colombo, N, Torri, V, Conte, P F, Fossati, R, Ravaioli, A, Mangioni, C
Publicado 2004

Phase II study of lonidamine in metastatic breast cancer.

por Pronzato, P., Amoroso, D., Bertelli, G., Conte, P. F., Cusimano, M. P., Ciottoli, G. B., Gulisano, M., Lionetto, R., Rosso, R.
Publicado 1989

Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study

por Tibaldi, C, Prochilo, T, Russo, F, Pennucci, M C, Del Freo, A, Innocenti, F, Fabbri, A, Falcone, A, Conte, P F, Baldini, E
Publicado 2006

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial

por Tubiana-Mathieu, N, Bougnoux, P, Becquart, D, Chan, A, Conte, P-F, Majois, F, Espie, M, Morand, M, Vaissiere, N, Villanova, G
Publicado 2009

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy

por Bengala, C, Bettelli, S, Bertolini, F, Sartori, G, Fontana, A, Malavasi, N, Depenni, R, Zironi, S, Del Giovane, C, Luppi, G, Conte, P F
Publicado 2010

Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Canc...

por Ardizzoni, A., Addamo, G. F., Baldini, E., Borghini, U., Portalone, L., De Marinis, F., Lionetto, R., Conte, P. F., Bruzzi, P., Pennucci, M. C.
Publicado 1995

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety

por Baldini, E, Prochilo, T, Salvadori, B, Bolognesi, A, Aldrighetti, D, Venturini, M, Rosso, R, Carnino, F, Gallo, L, Giannessi, P, Conte, P F, Orlandini, C, Bruzzi, P
Publicado 2004

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study

por Bengala, C, Zamagni, C, Pedrazzoli, P, Matteucci, P, Ballestrero, A, Da Prada, G, Martino, M, Rosti, G, Danova, M, Bregni, M, Jovic, G, Guarneri, V, Maur, M, Conte, P F
Publicado 2006

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma

por Bengala, C, Guarneri, V, Giovannetti, E, Lencioni, M, Fontana, E, Mey, V, Fontana, A, Boggi, U, Del Chiaro, M, Danesi, R, Ricci, S, Mosca, F, Del Tacca, M, Conte, P F
Publicado 2005

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer

por Bertolini, F, Malavasi, N, Scarabelli, L, Fiocchi, F, Bagni, B, Giovane, C Del, Colucci, G, Gerunda, G E, Depenni, R, Zironi, S, Fontana, A, Pettorelli, E, Luppi, G, Conte, P F
Publicado 2011

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer

por Cappuzzo, F, Mazzoni, F, Gennari, A, Donati, S, Salvadori, B, Orlandini, C, Cetto, G L, Molino, A, Galligioni, E, Mansutti, M, Tumolo, S, Lucentini, A, Valduga, F, Bartolini, S, Crinò, L, Conte, P F
Publicado 2004

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study

por Conte, P F, Donati, S, Gennari, A, Guarneri, V, Orlandini, C, Rondini, M, Roncella, M, Marini, L, Collecchi, P, Viacava, P, Naccarato, A G, Degli Esposti, R, Bonardi, S, Bottini, A, Saracchini, S, Tumolo, S, Gullo, G, Santoro, A, Crino, L
Publicado 2005

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study

por Guarneri, V, Dieci, M V, Bisagni, G, Frassoldati, A, Bianchi, G V, De Salvo, G L, Orvieto, E, Urso, L, Pascual, T, Paré, L, Galván, P, Ambroggi, M, Giorgi, C A, Moretti, G, Griguolo, G, Vicini, R, Prat, A, Conte, P F
Publicado 2019

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

por Aabo, K., Adams, M., Adnitt, P., Alberts, D. S., Athanazziou, A., Barley, V., Bell, D. R., Bianchi, U., Bolis, G., Brady, M. F., Brodovsky, H. S., Bruckner, H., Buyse, M., Canetta, R., Chylak, V., Cohen, C. J., Colombo, N., Conte, P. F., Crowther, D., Edmonson, J. H., Gennatas, C., Gilbey, E., Gore, M., Guthrie, D., Yeap, B. Y.
Publicado 1998